logo-loader
viewBioCorRx Inc.

Full interview: BioCorRx continues to advance BICX102 naltrexone implant through regulatory approval process

BioCorRX (OTCQB: BICX) CEO Brady Granier joined Steve Darling from Proactive Vancouver on Skype to discuss the company getting their second tranche of a funding grant that was awarded by the National Institute on Drug Abuse. Granier talked about receiving this funding and what it will ve used for. 

Granier also told Proactive about their product BICX102 and wherein the pipeline it is.

Quick facts: BioCorRx Inc.

Price: 2.7 USD

OTCMKTS:BICX
Market: OTCQB
Market Cap: $14.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioCorRx Inc. named herein, including the promotion by the Company of BioCorRx Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioCorRx says COVID-19 will not delay their work on...

BioCorRx (OTCMKTS: BICX) CEO Brady Granier joined Steve Darling from Proactive in Vancouver to discuss if their business and research are being affected by the outbreak of COVID-19. Granier telling Proactive some of the ways the company is able to continue their works especially when it...

on 2/4/20

2 min read